Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This multicenter, open-label study assessed the clinical efficacy and tolerability of the proton-pump inhibitor rabeprazole 20 mg once daily in 189 patients with functional dyspepsia and normal findings on upper endoscopy. The clinical efficacy rate was 86% after only 4 weeks of treatment, and symptoms remained under control at the end of 4 weeks without treatment. Rabeprazole was well tolerated and was associated with a low incidence (8%) of mild, transient adverse events.
 ...
PMID:Latin American open-label study with rabeprazole in patients with functional dyspepsia. Mexican Rabeprazole Investigators Group. 1118 58

The results of two treatment types of the patients with chronic gastritis and with non-ulcerative functional dyspepsia (NFD) at reflux-similar variant are represented. The patients received Omeprasol (Losec) or Rabeprasol (Pariet) accordingly 20 mg once per day in the morning, 30-60 minutes before the breakfast. The treatment course was 7 days. The investigations have shown the following: the level of acidity has decreased in all the patients treated by Rabeprasol, normal acidity is detected in the all 15 patients, the level of gastric acidity has decreased in the patients, treated by Omeprasol. However the hyperacidity was preserved in 10 from 12 patients.
 ...
PMID:[Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type]. 1204 84